EOLS — Evolus, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1570562 ·
Last close
$8.78
Market Cap
$579.92M
52W High
$8.82
52W Low
$5.45
ADV30
926,976
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 84,084,000 | 57,180,000 | -3,293,000 | -8,052,000 | 248,024,000 | 45,170,000 | 278,927,000 |
| Mar 2026 | 73,137,000 | 48,897,000 | -6,862,000 | -10,674,000 | 220,646,000 | 49,792,000 | 249,427,000 |
| Dec 2025 | 90,300,000 | 59,291,000 | -291,000 | 130,000 | 225,868,000 | 53,826,000 | 248,974,000 |
| Sep 2025 | 68,967,000 | 45,841,000 | -10,164,000 | -15,737,000 | 218,997,000 | 43,523,000 | 247,757,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,381,000
Investing CF
$-6,515,000
Financing CF
$5,559,000
CapEx
$-6,515,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-679,766,000
Inventory
$40,896,000
Receivables
$62,383,000
ST Investments
—
EBIT TTM
$-17,460,000
Pretax Income TTM
$-33,679,000
Interest Exp TTM
$16,219,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$316,488,000
EBITDA
$-11,723,000
Free Cash Flow
$-1,162,125
Enterprise Value
$673,797,184
Total Cash
$45,170,000
Total Debt
$164,804,000
Shares Out
66,050,440
Trailing EPS
$-0.53
Book Value
$-0.47
ROE
—
ROA
-5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 297,176,000 | -37,600,000 | -51,641,000 | 225,868,000 | 248,974,000 | — | -42,265,000 |
| Dec 2024 | 266,274,000 | -27,235,000 | -50,420,000 | 232,569,000 | 227,047,000 | — | -17,999,000 |
| Dec 2023 | 202,085,000 | -44,976,000 | -61,685,000 | 188,998,000 | 209,687,000 | — | -34,008,000 |
| Dec 2022 | 148,616,000 | -59,575,000 | -74,412,000 | 177,983,000 | 159,484,000 | — | -84,912,000 |
TTM Snapshot
Revenues TTM
$177,504,000
NetIncome TTM
$-67,982,000
OpCashFlow TTM
$0
Assets (Latest)
$232,569,000
Forward EPS
$0.28
Max Pain — expiry 2027-01-15
max pain strike: $7.50 · spot: $8.78 · call oi: 4,715 · put oi: 67
Expected Move to 2027-01-15:
±$4.90
(55.81%) —
implied range
$3.88 –
$13.68
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | $602.46M | $4.80 | — |
| ALT | Altimmune, Inc. | $604.95M | $3.11 | — |
| OVID | Ovid Therapeutics Inc. | $550.74M | $2.82 | — |
| ARVN | ARVINAS, INC. | $610.71M | $9.34 | — |
| CTNM | Contineum Therapeutics, Inc. | $548.10M | $16.63 | — |
News headlines (Yahoo Finance, 1h cache)
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...
2026-08-06 05:07 · Yahoo
Evolus Q2 Earnings Call Highlights
2026-08-06 01:03 · Yahoo
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Evolus, Inc. Q1 2026 Earnings Call Summary
2026-05-05 00:23 · Yahoo
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
2026-05-04 23:30 · Yahoo
Evolus Q1 Earnings Call Highlights
2026-05-04 22:17 · Yahoo
Evolus (EOLS) Q2 2025 Earnings Call Transcript
2026-05-04 20:34 · Yahoo
Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
2026-08-17 14:56 · Yahoo
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
2026-08-11 13:55 · Yahoo
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
2026-08-06 00:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.